BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Elironrasib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Elironrasib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05462717-1997@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Elironrasib: Phase 1 readout est. (NCT05462717)
DESCRIPTION:Elironrasib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Dos
 e Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects 
 With Advanced KRASG12C Mutant Solid Tumors\nEstimated primary completion: 
 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eliron
 rasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05462717
URL:https://assetmemo.bio/drug/elironrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-1997@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Elironrasib: Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Elironrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC\nEs
 timated primary completion: June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/elironrasib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/elironrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128551-1997@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Elironrasib: Phase 1/2 readout est. (NCT06128551)
DESCRIPTION:Elironrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Ther
 apy in Participants With Advanced KRAS G12C Mutant Solid Tumors\nEstimated
  primary completion: December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/elironrasib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06128551
URL:https://assetmemo.bio/drug/elironrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-1997@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Elironrasib: Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Elironrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients Wit
 h Solid Tumors\nEstimated primary completion: May 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/elironrasib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/elironrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
